Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.

MLA

Odeniyide, Patience, et al. “Targeting Farnesylation as a Novel Therapeutic Approach in HRAS-Mutant Rhabdomyosarcoma.” Oncogene, vol. 41, no. 21, May 2022, pp. 2973–83. EBSCOhost, https://doi.org/10.1038/s41388-022-02305-x.

APA

Odeniyide, P., Yohe, M. E., Pollard, K., Vaseva, A. V., Calizo, A., Zhang, L., Rodriguez, F. J., Gross, J. M., Allen, A. N., Wan, X., Somwar, R., Schreck, K. C., Kessler, L., Wang, J., & Pratilas, C. A. (2022). Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene, 41(21), 2973–2983. https://doi.org/10.1038/s41388-022-02305-x

Chicago

Odeniyide, Patience, Marielle E Yohe, Kai Pollard, Angelina V Vaseva, Ana Calizo, Lindy Zhang, Fausto J Rodriguez, et al. 2022. “Targeting Farnesylation as a Novel Therapeutic Approach in HRAS-Mutant Rhabdomyosarcoma.” Oncogene 41 (21): 2973–83. doi:10.1038/s41388-022-02305-x.